Skip to main content

01.11.2015 | Clinical Study

Accuracy of Tokuhashi score system in predicting survival of lung cancer patients with vertebral metastasis

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Controversy exists in the accuracy of Tokuhashi score (TS) system in predicting survival of patients with vertebral metastasis, including vertebral metastases from primary lung cancer. To calculate the accuracy of the TS in predicting survival of lung cancer patients with vertebral metastasis and investigate which subgroup’s survival is suitable for TS to predict, we conduct this retrospective study. From January 2008 to December 2013, 151 patients with vertebral metastases from primary lung cancer in our institute were included. The data were censored at December 2014. Patients were classified according to TS. The actual and predicted survivals were compared to calculate the accuracy rate. Spearman’s correlation analysis was conducted to explore the relation between overall survival and TS. Cox regression was carried out to investigate potential factors affecting prognosis. Only 8.6 % (13 patients) actually followed the survivorship pattern as predicted by the TS. Spearman’s correlation analysis demonstrated that actual overall survival correlated significantly with the TS. Cox model indicated that status of visceral metastases (i.e., none, involved with lung, involved with extrapulmonary organ) and response to first-time systemic therapy (effective or not) are associated significantly with overall survival. For patients with visceral metastases and progression to first-time systemic therapy simultaneously, predicted survival by TS and actual survival matched well. TS could only predict survival accurately in those with visceral metastases and disease progression to first-time systemic therapy simultaneously. Thus, it may not be a reliable tool to predict survival in lung cancer patients with vertebral metastasis. Status of visceral metastases and response to first-time systemic therapy should be added into TS system to increase validity and accuracy.
Literatur
1.
Zurück zum Zitat Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sCrossRefPubMed Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sCrossRefPubMed
2.
Zurück zum Zitat Coello MC, Luketich JD, Litle VR, Godfrey TE (2004) Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer 5:214–225CrossRefPubMed Coello MC, Luketich JD, Litle VR, Godfrey TE (2004) Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer 5:214–225CrossRefPubMed
3.
Zurück zum Zitat Al Husaini HMD, Wheatley-Price PMM, Clemons MMF et al (2009) Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol 4:251–259CrossRefPubMed Al Husaini HMD, Wheatley-Price PMM, Clemons MMF et al (2009) Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol 4:251–259CrossRefPubMed
4.
Zurück zum Zitat Bae HM, Lee SH, Kim TM et al (2012) Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer 77:572–577CrossRefPubMed Bae HM, Lee SH, Kim TM et al (2012) Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer 77:572–577CrossRefPubMed
5.
Zurück zum Zitat Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s–6249sCrossRefPubMed Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s–6249sCrossRefPubMed
6.
7.
Zurück zum Zitat Abrams HL, Spiro R, Goldstein N (1950) Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 3(1):74–85CrossRefPubMed Abrams HL, Spiro R, Goldstein N (1950) Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 3(1):74–85CrossRefPubMed
8.
Zurück zum Zitat Sze WM, Shelley MD, Held I et al (2003) Palliation of metastatic bone pain: single fraction versus multi-fraction radiotherapy—a systemic review of randomised trials. Clin Oncol (R Coll Radiol) 15(6):345–352CrossRef Sze WM, Shelley MD, Held I et al (2003) Palliation of metastatic bone pain: single fraction versus multi-fraction radiotherapy—a systemic review of randomised trials. Clin Oncol (R Coll Radiol) 15(6):345–352CrossRef
9.
Zurück zum Zitat Singh K, Samartzis D, Vaccaro AR et al (2006) Current concepts in the management of metastatic spinal disease. The role of minimallyinvasive approaches. J Bone Joint Surg Br 88(4):434–442CrossRefPubMed Singh K, Samartzis D, Vaccaro AR et al (2006) Current concepts in the management of metastatic spinal disease. The role of minimallyinvasive approaches. J Bone Joint Surg Br 88(4):434–442CrossRefPubMed
10.
Zurück zum Zitat Jónsson B, Jónsson H Jr, Karlström G et al (1994) Surgery of cervical spine metastases: a retrospective study. Eur Spine J 3:76–83CrossRefPubMed Jónsson B, Jónsson H Jr, Karlström G et al (1994) Surgery of cervical spine metastases: a retrospective study. Eur Spine J 3:76–83CrossRefPubMed
11.
Zurück zum Zitat Riegel T, Schilling T, Sitter H et al (2002) Analysis of factors affecting the prognosis of vertebral metastases. Zentralbl Neurochir 63(19):2–6CrossRefPubMed Riegel T, Schilling T, Sitter H et al (2002) Analysis of factors affecting the prognosis of vertebral metastases. Zentralbl Neurochir 63(19):2–6CrossRefPubMed
12.
Zurück zum Zitat Hosono N, Ueda T, Tamura D et al (2005) Prognostic relevance of clinical symptoms in patients with spinal metastases. Clin Orthop Relat Res 436:196–201CrossRefPubMed Hosono N, Ueda T, Tamura D et al (2005) Prognostic relevance of clinical symptoms in patients with spinal metastases. Clin Orthop Relat Res 436:196–201CrossRefPubMed
13.
Zurück zum Zitat Jansson KA, Bauer HCF (2006) Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbal spinal metastases. Eur Spine J 15:196–202PubMedCentralCrossRefPubMed Jansson KA, Bauer HCF (2006) Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbal spinal metastases. Eur Spine J 15:196–202PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Schaser KD, Melcher I, Mittlmeier T et al (2007) Surgical management of vertebral column metastatic disease. Unfallchirurg 110(2):137–159CrossRefPubMed Schaser KD, Melcher I, Mittlmeier T et al (2007) Surgical management of vertebral column metastatic disease. Unfallchirurg 110(2):137–159CrossRefPubMed
15.
Zurück zum Zitat Tokuhashi Y, Yasumitsu A, Umezawa N (2009) Outcome of treatment for spinal metastases using scoring system for preoperative evaluation of prognosis. Spine 34:69–73CrossRefPubMed Tokuhashi Y, Yasumitsu A, Umezawa N (2009) Outcome of treatment for spinal metastases using scoring system for preoperative evaluation of prognosis. Spine 34:69–73CrossRefPubMed
16.
Zurück zum Zitat Pointillart V, Vital J, Salmi R, Diallo A, Quan GM (2011) Survival prognostic factors and clinical outcomes in patients with spinal metastases. J Cancer Res Clin Oncol 137:849–856CrossRefPubMed Pointillart V, Vital J, Salmi R, Diallo A, Quan GM (2011) Survival prognostic factors and clinical outcomes in patients with spinal metastases. J Cancer Res Clin Oncol 137:849–856CrossRefPubMed
17.
Zurück zum Zitat Choi D, Crockard A, Bunger C et al (2010) Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the Global Spine Tumour Study Group. Eur Spine J 19:215–222PubMedCentralCrossRefPubMed Choi D, Crockard A, Bunger C et al (2010) Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the Global Spine Tumour Study Group. Eur Spine J 19:215–222PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Tokuhashi Y, Matsuzaki H, Oda H et al (2005) A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976) 30:2186–2191CrossRef Tokuhashi Y, Matsuzaki H, Oda H et al (2005) A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976) 30:2186–2191CrossRef
19.
Zurück zum Zitat Ulmar B, Huch K, Naumann U et al (2007) Evaluation of the Tokuhashi prognosis score and its modifications in 217 patients with vertebral metastases. Eur J Surg Oncol 33:914–919CrossRefPubMed Ulmar B, Huch K, Naumann U et al (2007) Evaluation of the Tokuhashi prognosis score and its modifications in 217 patients with vertebral metastases. Eur J Surg Oncol 33:914–919CrossRefPubMed
20.
Zurück zum Zitat Ulmar B, Richter M, Cakir B et al (2005) The Tokuhashi score: significant predictive value for the life expectancy of patients with breast cancer with spinal metastases. Spine (Phila Pa 1976) 30:2222–2226CrossRef Ulmar B, Richter M, Cakir B et al (2005) The Tokuhashi score: significant predictive value for the life expectancy of patients with breast cancer with spinal metastases. Spine (Phila Pa 1976) 30:2222–2226CrossRef
21.
Zurück zum Zitat Yamashita T, Siemionow KB, Mroz TE et al (2011) A prospective analysis of prognostic factors in patients with spinal metastases: use of the revised Tokuhashi score. Spine (Phila Pa 1976) 36:910–917CrossRef Yamashita T, Siemionow KB, Mroz TE et al (2011) A prospective analysis of prognostic factors in patients with spinal metastases: use of the revised Tokuhashi score. Spine (Phila Pa 1976) 36:910–917CrossRef
22.
Zurück zum Zitat Putz C, Wiedenhofer B, Gerner HJ et al (2008) Tokuhashi prognosis score: an important tool in prediction of the neurological outcome in metastatic spinal cord compression: a retrospective clinical study. Spine (Phila Pa 1976) 33:2669–2674CrossRef Putz C, Wiedenhofer B, Gerner HJ et al (2008) Tokuhashi prognosis score: an important tool in prediction of the neurological outcome in metastatic spinal cord compression: a retrospective clinical study. Spine (Phila Pa 1976) 33:2669–2674CrossRef
23.
Zurück zum Zitat Quraishi NA, Manoharan SR, Arealis G et al (2013) Accuracy of the revised Tokuhashi score in predicting survival in patients with metastatic spinal cord compression (MSCC). Eur Spine J 22(Suppl 1):21–26PubMedCentralCrossRef Quraishi NA, Manoharan SR, Arealis G et al (2013) Accuracy of the revised Tokuhashi score in predicting survival in patients with metastatic spinal cord compression (MSCC). Eur Spine J 22(Suppl 1):21–26PubMedCentralCrossRef
24.
Zurück zum Zitat Gakhar H, Swamy GN, Bommireddy R et al (2013) A study investigating the validity of modified Tokuhashi score to decide surgical intervention in patients with metastatic spinal cancer. Eur Spine J 22:565–568PubMedCentralCrossRefPubMed Gakhar H, Swamy GN, Bommireddy R et al (2013) A study investigating the validity of modified Tokuhashi score to decide surgical intervention in patients with metastatic spinal cancer. Eur Spine J 22:565–568PubMedCentralCrossRefPubMed
25.
Zurück zum Zitat Papastefanou S, Alpantaki K, Akra G, Katonis P (2012) Predictive value of Tokuhashi and Tomita scores in patients with metastatic spine disease. Acta Orthop Traumatol Turc. 46(1):50–56CrossRefPubMed Papastefanou S, Alpantaki K, Akra G, Katonis P (2012) Predictive value of Tokuhashi and Tomita scores in patients with metastatic spine disease. Acta Orthop Traumatol Turc. 46(1):50–56CrossRefPubMed
26.
Zurück zum Zitat Kim J, Lee SH, Park SJ, Chung SS, Kim ES, Eoh W, Lee CS (2014) Analysis of the predictive role and new proposal for surgical strategies based on the modified Tomita and Tokuhashi scoring systems for spinal metastasis. World J Surg Oncol 12:245PubMedCentralCrossRefPubMed Kim J, Lee SH, Park SJ, Chung SS, Kim ES, Eoh W, Lee CS (2014) Analysis of the predictive role and new proposal for surgical strategies based on the modified Tomita and Tokuhashi scoring systems for spinal metastasis. World J Surg Oncol 12:245PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Aoude A (2014) Amiot LP.A comparison of the modified Tokuhashi and Tomita scores in determining prognosis for patients afflicted with spinal metastasis. Can J Surg 57(3):188–193PubMedCentralCrossRefPubMed Aoude A (2014) Amiot LP.A comparison of the modified Tokuhashi and Tomita scores in determining prognosis for patients afflicted with spinal metastasis. Can J Surg 57(3):188–193PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Hernandez-Fernandez A, Vélez R, Lersundi-Artamendi A, Pellisé F (2012) External validity of the Tokuhashi score in patients with vertebral metastasis. J Cancer Res Clin Oncol 138(9):1493–1500CrossRefPubMed Hernandez-Fernandez A, Vélez R, Lersundi-Artamendi A, Pellisé F (2012) External validity of the Tokuhashi score in patients with vertebral metastasis. J Cancer Res Clin Oncol 138(9):1493–1500CrossRefPubMed
29.
Zurück zum Zitat Hessler C, Vettorazzi E, Madert J, Bokemeyer C, Panse J (2011) Actual and predicted survival time of patients with spinal metastases of lung cancer: evaluation of the robustness of the Tokuhashi score. Spine (Phila Pa 1976) 36(12):983–989CrossRef Hessler C, Vettorazzi E, Madert J, Bokemeyer C, Panse J (2011) Actual and predicted survival time of patients with spinal metastases of lung cancer: evaluation of the robustness of the Tokuhashi score. Spine (Phila Pa 1976) 36(12):983–989CrossRef
30.
Zurück zum Zitat Park S, Lee C, Chung S, Lee K (2014) How accurately can Tokuhashi score system predict the survival in the current practice for spinal metastases? Prospective analysis of consecutive 145 patients between 2007 and 2013. J Spinal Disord Tech [Epub ahead of print] Park S, Lee C, Chung S, Lee K (2014) How accurately can Tokuhashi score system predict the survival in the current practice for spinal metastases? Prospective analysis of consecutive 145 patients between 2007 and 2013. J Spinal Disord Tech [Epub ahead of print]
31.
Zurück zum Zitat Gangi A, Sabharwal T, Irani FG, Buy X, Morales JP, Adam A (2006) Quality assurance guidelines for percutaneous vertebroplasty. Cardiovasc Intervent Radiol 29:173–178CrossRefPubMed Gangi A, Sabharwal T, Irani FG, Buy X, Morales JP, Adam A (2006) Quality assurance guidelines for percutaneous vertebroplasty. Cardiovasc Intervent Radiol 29:173–178CrossRefPubMed
32.
Zurück zum Zitat McGraw JK, Cardella J, Barr JD et al (2003) Society of Interventional Radiology quality improvement guidelines for percutaneous vertebroplasty. J Vasc Interv Radiol 14:827–831CrossRefPubMed McGraw JK, Cardella J, Barr JD et al (2003) Society of Interventional Radiology quality improvement guidelines for percutaneous vertebroplasty. J Vasc Interv Radiol 14:827–831CrossRefPubMed
33.
Zurück zum Zitat Wang Z, Zhen Y, Wu C, Li H, Yang Y, Shen Z, Zhao H, Yao Y (2012) CT fluoroscopy-guided percutaneous osteoplasty for the treatment of osteolytic lung cancer bone metastases to the spine and pelvis. J Vasc Interv Radiol 23(9):1135–1142CrossRefPubMed Wang Z, Zhen Y, Wu C, Li H, Yang Y, Shen Z, Zhao H, Yao Y (2012) CT fluoroscopy-guided percutaneous osteoplasty for the treatment of osteolytic lung cancer bone metastases to the spine and pelvis. J Vasc Interv Radiol 23(9):1135–1142CrossRefPubMed
34.
Zurück zum Zitat Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV (2014) Extending survival of stage IV non-small cell lung cancer. Semin Oncol 41(1):69–92CrossRefPubMed Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV (2014) Extending survival of stage IV non-small cell lung cancer. Semin Oncol 41(1):69–92CrossRefPubMed
35.
Zurück zum Zitat Faria SL (2014) Role of radiotherapy in metastatic non-small cell lung cancer. Front Oncol 13(4):22 Faria SL (2014) Role of radiotherapy in metastatic non-small cell lung cancer. Front Oncol 13(4):22
36.
37.
Zurück zum Zitat Jeremic B, Casas F, Wang L, Perin B (2010) Radiochemotherapy in extensive disease small cell lung cancer ED-SCLC. Front Radiat Ther Oncol 42:180–186CrossRefPubMed Jeremic B, Casas F, Wang L, Perin B (2010) Radiochemotherapy in extensive disease small cell lung cancer ED-SCLC. Front Radiat Ther Oncol 42:180–186CrossRefPubMed
38.
Zurück zum Zitat Wolf M, Tebbe S, Fink T (2004) First-line chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer 45(Suppl 2):S223–S234CrossRefPubMed Wolf M, Tebbe S, Fink T (2004) First-line chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer 45(Suppl 2):S223–S234CrossRefPubMed
39.
Zurück zum Zitat Kim YH, Mishima M (2011) Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev 37(2):143–150CrossRefPubMed Kim YH, Mishima M (2011) Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev 37(2):143–150CrossRefPubMed
40.
Zurück zum Zitat Noda K, Nishiwaki Y, Kawahara M et al (2002) Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell-lung cancer. N Engl J Med 346(2):85–91CrossRefPubMed Noda K, Nishiwaki Y, Kawahara M et al (2002) Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell-lung cancer. N Engl J Med 346(2):85–91CrossRefPubMed
Metadaten
Titel
Accuracy of Tokuhashi score system in predicting survival of lung cancer patients with vertebral metastasis
Publikationsdatum
01.11.2015
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2015
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-015-1934-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.